Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656814 | 0.88 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL10506606 | 0.84 | SLC6A4 (0.68) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL30236392 | 0.83 | SLC6A4 (0.61) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL13354941 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL334384 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586261 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL9633193 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL334385 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586263 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL16767542 | 0.82 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | SLC6A4 421/4885CYP1A2 392/4885CYP2D6 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.